AngioDynamics, Inc. (ANGO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$15.20-1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ANGO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue efforts to generate positive free cash flow for the full fiscal year 2026.
Stated as a priority in 5 of last 5 quarters. Management consistently guided for positive free cash flow for FY 2026. However, cash from operating activities fluctuated significantly, with negative $3.11M in 2026-Q3 versus positive $2.47M in 2025-Q2, indicating limited progress toward sustained positive free cash flow.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Free Cash Flow Unchanged Positive for full year FY 2026”
“Free Cash Flow Unchanged Positive for full year FY 2026”
“Free Cash Flow Unchanged Positive for full year FY 2026”
“Free Cash Flow Positive for Full Year FY2026”
“Free Cash Flow Positive for Full Year FY2026”
Sustain gross margin within the targeted range of 53.5% to 55.5% as a key operational metric.
Stated as a priority in 5 of last 5 quarters. Management targets gross margin between 53.5% and 55.5%. Actual gross margin calculated from reported gross profit and revenue ranged approximately 51.7% to 56.0%, slightly below target in recent quarters, indicating limited progress maintaining the margin within the stated range.
“Gross Margin Unchanged 53.5% - 55.5%”
“Gross Margin Unchanged 53.5% - 55.5%”
“Gross Margin Unchanged 53.5% - 55.5%”
“Gross Margin 53.5% - 55.5%”
“Gross Margin 53.5% - 55.5%”
Grow net sales to the guided range of $313.5 million to $315.5 million for fiscal year 2026.
Stated as a priority in 5 of last 5 quarters. Management guided net sales growth to $313.5M-$315.5M for FY 2026, up from prior guidance of $308M-$313M. Reported quarterly revenue grew from $67.5M in 2025-Q1 to $78.4M in 2026-Q3, showing progress toward the sales growth target.
“Net Sales Increased $313.5 - $315.5 M”
“Net Sales Increased $312 - $314 million”
“Net Sales Increased $308 - $313 million”
“Net Sales Increased $308 - $313 million”
“Net Sales Increased $305 - $310 million”
Pursue and establish strategic partnerships to support growth and innovation.
Newly stated in 2 of last 5 quarters. Management disclosed strategic partnerships in 2026-Q2 and 2026-Q3 8-K filings. No direct financial impact data is available yet, indicating early-stage progress on this growth initiative.
“ANGO — strategic partnership announced in Form 8-K”
“ANGO — strategic partnership announced in Form 8-K”
Defend proprietary technology by pursuing patent infringement lawsuits.
Newly stated in 2026-Q2. Management filed a patent infringement lawsuit to protect proprietary technology. No financial impact or progress data is available yet, indicating an early stage legal priority.
“Filed patent infringement lawsuit against Endovascular Engineering”
Over the trailing year it converted -61.26x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
14 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.